Register for HGS 2021
Let’s Make Itching Ancient History
Why should you attend?
Cutting Edge Topics
So, invite your friends and colleagues
Choose Your Language Elige tu idioma Choisissez votre langue Wähle deine Sprache Scegli la tua LINGUA Escolha seu idioma Kies je taal Выберите свой язык 言語を選択してください 당신의 언어를 고르시 오 選擇你的語言
Simultaneous translation available event-wide: Traducción simultánea disponible en todo el evento: Traduction simultanée disponible dans tout l'événement: Simultanübersetzung ereignisweit verfügbar: Traduzione simultanea disponibile a livello di evento: Tradução simultânea disponível em todo o evento: Simultane vertaling beschikbaar voor het hele evenement: Синхронный перевод доступен по всему мероприятию: イベント全体で利用可能な同時翻訳： 이벤트 전체에서 동시 번역 가능 : 活動範圍內可同時進行翻譯：
- 0.5 RACE credit / 30 min lecture
- Approved by the AAVSB
HGS 2021 Program
Each lecture has been approved by the AAVSB RACE for 0.5 hrs of CE credits.
Atopic Dermatitis (AD) is the most common inflammatory skin disease in humans. During the past ten years there has been a revolution in our understanding of key mechanisms driving AD. It is now known that skin barrier dysfunction and immune dysregulation are key features of AD. New therapies are pathogenesis-based targeting skin barrier dysfunction and polarize immune pathways driving AD.
In this session we will cover the causes of pruritus in dogs and the basic clinical approach to determining its correct origin in the canine patient. This topic will be discussed in a clinically applicable manner while outlining hallmark differences between the various differentials.
In human medicine, teledermatology is an efficient method of evaluating a patient using smartphones, tablets, computers and appropriate software. It is best when the patient, parent or pet owner has the ability to navigate software with video capability. Software like Zoom can help to visualize the skin conditions of concern. It is also remarkable what can be diagnosed and treated even over the telephone when the observer can provide clear verbal descriptions and/or send still photographs to enhance the clinical process.
Multimodal Therapy represents a profound change in our thinking about how best to treat canine atopic dermatitis. Within this concept, it’s important to recognize the difference between a foundation treatment (which creates the bulk of control) and an accessory treatment (which helps the foundation treatment to work). Foundation and accessory treatments each serve unique and intersecting roles in the overall plan. For foundation treatments, the concept of targeting is critical to understand as it can help in treatment selection. It is also helpful (both for you and your client) to frame your treatment plan as a “short term vs. long term” approach. Short term, providing immediate relief is paramount, usually involving drug treatment. Longer term, strategies such as avoidance, control of flare factors, augmenting efficacy of medications, and preventive strategies serve to create lifelong relief while maximizing patient safety.
The “art of practicing veterinary dermatology” inevitably involves many lotions, potions and magic tricks! Some may consider these practices “hocus pocus” and others consider them “tried and true”… In this lecture we will discuss debunking a few of the myths that circulate among veterinarians and clients, when it comes to veterinary dermatology diagnostics and therapies.
This presentation will review the evidence supporting use of specific nutrients in the management of canine atopic dermatitis. We will also review the role nutrition plays in combating the mechanisms involved in canine atopic dermatitis as part of multimodal therapy and share information about a new nutritional solution for dogs with canine atopic dermatitis.
Appropriate management of atopic dermatitis requires a number of actions on the part of pet parents – e.g., to have diagnostic tests, provide appropriate nutrition, antimicrobial therapy etc. Given how central people are to managing atopic dermatitis, this talk will describe how psychology can help to understand whether and why pet parents take appropriate action. The answer is divided into two issues – motivation and volition. Motivation is understood in terms of Protection Motivation Theory (Rogers, 1975) which suggests that people are motivated to protect their dog when (i) the threat is appraised as severe and likely to occur and (ii) they believe that the proposed actions are likely to be effective in reducing the threat. Volition refers to the challenges encountered translating motivation (or good intentions) into action and will be discussed with reference to Control Theory (Carver & Scheier, 1982), which suggests that having set a goal (e.g., to deliver solutions) people need to keep track of their progress and take action when needed. The final part of the talk will discuss how psychology can help veterinarians raise the (difficult) topic of skin conditions with owners (e.g., how they might reduce defensiveness) and enable clients to deliver the solutions appropriately (e.g., via a step-by-step approach).
Speakers: Donald Leung, Darren Berger, Richard Usatine, Douglas J. DeBoer, Christina Restrepo, Dana Hutchinson, Thomas L. Webb
In this lecture we’ll cover our groundbreaking work that spanned 4 years, 3 clinical studies, 2 disorders; food and environmental allergies and the single food that is clinically shown to help manage both conditions.
This session will review the common myths related to dermatology and nutrition. Strategies for addressing client concerns related to each myth will be provided. We will also review tips for client communication and for achieving compliance when managing pets with dermatological disease that is suspected to be diet-related.
The availability of Oclacitinib maleate (Apoquel®) and Lokivetmab (Cytopoint™) has increased the success in the management of canine atopic dermatitis. Oclacitinib is a synthetic janus kinase (JAK) inhibitor developed for the treatment of allergic skin diseases in dogs. It has a high degree of efficacy, a rapid speed of onset and fewer adverse effects than corticosteroids. It has been shown to be safe and efficacious for long-term use and improved the quality of life for dogs with atopic dermatitis. Cytopoint™ is the first monoclonal antibody (mAb) therapy approved for control of the clinical signs associated with atopic dermatitis in dogs. Cytopoint is an injectable containing a caninized mAb specifically designed to target and neutralize cytokine interleukin-31 (IL-31). Having these drugs with a comparably high degree of efficacy has been extremely beneficial for the management of atopic dermatitis. The question of which drug to select for an individual patient is based on many variables but should occur on a case-by-case basis. The presentation will cover the when and how to use these drugs in clinical practice.
Social media is everywhere! With the right type of posting, it can be used as a powerful educational tool for veterinarians and clients. Since dermatology is such a visual specialty, using pictures through social media can be a fun way to engage your clinic clientele and other veterinary clinics. But it is important to have a variety of posts to keep content fresh and appealing to different followers. From clinical lesions to fun patient pictures, keeping your audience interested while taking the opportunity to teach can be a delicate balance. Learn the best types of posts such as before and after photos, action shots within the clinics, and videos that can allow the dermatology service at your veterinary hospital to thrive.
Speakers: Jennifer MacLeay, Jennifer A. Larsen, Julie Churchill, Wayne Rosenkrantz, Ashley Bourgeois
Don't Miss Out!
Save your seat for one of the most exciting CE events and learn from the comfort of your home!
Register now! With every registration to this website, Hill’s will donate $1 USD (up to $15,000) to the League of VetaHumanz, which is committed to excellence through diversity, equity and inclusion in veterinary medicine.